Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial.
The Swiss drugmaker said the Phase III trial data on treating the condition known as IgA nephropathy would support a request in 2026 for traditional US regulatory market approval.
&uuid=(email))